| pubmed-article:20720210 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0026724 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0031150 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0039198 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0971858 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C1413323 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0599946 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:20720210 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:20720210 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:20720210 | pubmed:dateCreated | 2010-9-3 | lld:pubmed |
| pubmed-article:20720210 | pubmed:abstractText | Mucosal (nasal or oral) administration of anti-CD3 mAb is effective in ameliorating animal models of autoimmunity (experimental autoimmune encephalomyelitis, diabetes, and lupus) by inducing LAP(+) regulatory T cells. We tested this approach in an arthritis model using type II collagen. We found that nasal anti-CD3 was more effective than oral anti-CD3 in attenuating the development of arthritis. Nasal anti-CD3 induced a LAP(+) regulatory T cell that secreted high levels of IL-10 and suppressed collagen-specific T cell proliferation and anti-collagen Ab production. However, neither nasal nor oral anti-CD3 attenuated disease when given to animals with ongoing arthritis, and this was associated with a lack of induction of LAP(+) regulatory T cells. We found, however, that coadministration of a novel emulsome adjuvant, which enhances Th2 responses, resulted in the induction of LAP(+) regulatory T cells and suppression of ongoing arthritis by both nasal and oral anti-CD3. Suppression of arthritis by mucosal anti-CD3 was associated with less joint damage, a decrease of TNF-alpha and IFN-gamma mRNA expression in joints, and a reduction in anti-collagen Abs. These results demonstrate that mucosal anti-CD3 therapy may serve as a therapeutic approach in arthritis and that the biologic effect is enhanced by an emulsome-based adjuvant. | lld:pubmed |
| pubmed-article:20720210 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20720210 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20720210 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20720210 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20720210 | pubmed:issn | 1550-6606 | lld:pubmed |
| pubmed-article:20720210 | pubmed:author | pubmed-author:WeinerHoward... | lld:pubmed |
| pubmed-article:20720210 | pubmed:author | pubmed-author:MaronRuthR | lld:pubmed |
| pubmed-article:20720210 | pubmed:author | pubmed-author:WuHenry YimHY | lld:pubmed |
| pubmed-article:20720210 | pubmed:author | pubmed-author:TukpahAnn-Mar... | lld:pubmed |
| pubmed-article:20720210 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20720210 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20720210 | pubmed:volume | 185 | lld:pubmed |
| pubmed-article:20720210 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20720210 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20720210 | pubmed:pagination | 3401-7 | lld:pubmed |
| pubmed-article:20720210 | pubmed:dateRevised | 2011-9-19 | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:meshHeading | pubmed-meshheading:20720210... | lld:pubmed |
| pubmed-article:20720210 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20720210 | pubmed:articleTitle | Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. | lld:pubmed |
| pubmed-article:20720210 | pubmed:affiliation | Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. | lld:pubmed |
| pubmed-article:20720210 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20720210 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20720210 | lld:pubmed |
